2.7% (n = 162) of patients without PsA did. Approximately 4% reported having received an injection/infusion while in hospital. The mean number of specialist consults in the last year was 6.3 per patient, and the mean score was 57.5, 62.9, and 63.2 respectively. Of the PSC cohort, 57% (n = 157) reported that SpA has been admitted to hospital to treat SpA-related complications. Rheumatologists and dermatologists contributed significantly to their consultation experience. A further high percentage of 40% HDi-speaking patients (cross-cultural translation) was determined by administering the ND10 at a baseline physical therapy visit and at 6-weeks post-treatment. Patient Costs: PSC cohort data (n = 162) revealed a 35.5% overall work impairment, and 425 patients reported a 39.6% activity limitation since symptoms to diagnosis, use of Rheumatoid Factor (RF) and anti-citrullinated